Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

518 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia.
Kawaguchi T, Komori A, Fujisaki K, Nishiguchi S, Kato M, Takagi H, Tanaka Y, Notsumata K, Mita E, Nomura H, Shibatoge M, Takaguchi K, Hattori T, Sata M, Koike K. Kawaguchi T, et al. Among authors: fujisaki k. Exp Ther Med. 2019 Jul;18(1):596-604. doi: 10.3892/etm.2019.7616. Epub 2019 May 24. Exp Ther Med. 2019. PMID: 31258695 Free PMC article.
Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy.
Mawatari S, Oda K, Kumagai K, Tabu K, Ijuin S, Fujisaki K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hori T, Taniyama O, Toyodome A, Sakae H, Hashiguchi M, Kure T, Sakurai K, Tamai T, Moriuchi A, Ido A. Mawatari S, et al. Among authors: fujisaki k. Hepatol Res. 2020 Apr;50(4):453-465. doi: 10.1111/hepr.13474. Epub 2020 Jan 16. Hepatol Res. 2020. PMID: 31846553
New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Inada Y, Uto H, Hiramine Y, Kure T, Fujisaki K, Hashiguchi M, Hori T, Oshige A, Imanaka D, Saishoji A, Taniyama O, Sakae H, Tamai T, Moriuchi A, Ido A. Mawatari S, et al. Among authors: fujisaki k. J Gastroenterol. 2017 Jul;52(7):855-867. doi: 10.1007/s00535-016-1303-0. Epub 2017 Jan 11. J Gastroenterol. 2017. PMID: 28078469
Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.
Mawatari S, Kumagai K, Oda K, Tabu K, Ijuin S, Fujisaki K, Tashima S, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Taniyama O, Toyodome A, Sakae H, Kure T, Sakurai K, Moriuchi A, Kanmura S, Ido A. Mawatari S, et al. Among authors: fujisaki k. PLoS One. 2022 Jan 12;17(1):e0262267. doi: 10.1371/journal.pone.0262267. eCollection 2022. PLoS One. 2022. PMID: 35020772 Free PMC article.
The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Fujisaki K, Hashiguchi M, Inada Y, Uto H, Hiramine Y, Kure T, Hori T, Taniyama O, Kasai A, Tamai T, Moriuchi A, Ido A. Mawatari S, et al. Among authors: fujisaki k. PLoS One. 2018 Jun 1;13(6):e0198642. doi: 10.1371/journal.pone.0198642. eCollection 2018. PLoS One. 2018. PMID: 29856885 Free PMC article.
Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
Tabu K, Mawatari S, Oda K, Kumagai K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Fujisaki K, Imanaka D, Kure T, Taniyama O, Toyodome A, Ijuin S, Sakae H, Sakurai K, Moriuchi A, Kanmura S, Ido A. Tabu K, et al. Among authors: fujisaki k. PLoS One. 2020 Aug 13;15(8):e0237475. doi: 10.1371/journal.pone.0237475. eCollection 2020. PLoS One. 2020. PMID: 32790728 Free PMC article.
518 results